Profile data is unavailable for this security.
About the company
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
- Revenue in DKK (TTM)344.25m
- Net income in DKK-738.75m
- Incorporated1997
- Employees270.00
- LocationZealand Pharma A/SSydmarken 11SOEBORG 2860DenmarkDNK
- Phone+45 88773600
- Fax+45 88773898
- Websitehttps://www.zealandpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BB BIOTECH AG | 2.08bn | 2.36bn | 16.82bn | -- | 7.04 | 0.8768 | -- | 8.09 | 5.62 | 5.62 | 4.91 | 45.11 | 0.0998 | -- | -- | -- | 11.35 | 2.34 | 12.96 | 2.52 | 97.74 | 99.06 | 113.67 | 35.40 | -- | -- | 0.1223 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
MorphoSys AG | 1.52bn | -3.40bn | 19.01bn | 464.00 | -- | -- | -- | 12.53 | -12.54 | -12.65 | 5.79 | -6.95 | 0.1002 | 1.86 | 4.58 | 388,358.00 | -22.47 | -10.25 | -27.58 | -11.61 | 83.89 | 85.92 | -224.25 | -78.53 | 1.38 | -- | -- | -- | -14.37 | 25.53 | -25.60 | -- | 3.11 | -- |
BACHEM HOLDING AG | 4.43bn | 858.85m | 51.68bn | 2.01k | 59.86 | 5.10 | 42.86 | 11.66 | 1.50 | 1.50 | 7.73 | 17.61 | 0.3765 | 1.23 | 3.33 | 287,794.60 | 7.29 | 8.85 | 8.17 | 10.28 | 30.65 | 31.63 | 19.38 | 19.74 | 3.04 | 29.80 | 0.0003 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
Qiagen NV | 13.34bn | 2.32bn | 62.75bn | 5.90k | 27.23 | 2.55 | 16.74 | 4.70 | 1.39 | 1.39 | 8.00 | 14.84 | 0.3209 | 1.84 | 5.64 | 299,838.70 | 5.58 | 5.41 | 6.63 | 6.53 | 62.78 | 64.65 | 17.38 | 16.35 | 1.45 | -- | 0.2946 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
Zealand Pharma A/S | 344.25m | -738.75m | 67.38bn | 270.00 | -- | 20.83 | -- | 195.73 | -12.52 | -12.52 | 5.78 | 45.56 | 0.1397 | 4.18 | 2.86 | 1,360,664.00 | -29.99 | -42.74 | -32.82 | -50.24 | 90.07 | 96.13 | -214.60 | -464.66 | 12.28 | -- | 0.1206 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
Genmab A/S | 17.76bn | 5.45bn | 116.07bn | 2.29k | 21.20 | 3.52 | -- | 6.53 | 82.80 | 82.80 | 269.74 | 498.87 | 0.5297 | -- | 4.51 | 8,059,438.00 | 16.25 | 17.43 | 17.48 | 18.59 | 74.05 | -- | 30.69 | 35.87 | 12.42 | -- | 0.0301 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
argenx SE | 9.69bn | -2.26bn | 178.04bn | 1.15k | -- | -- | -- | 18.37 | -5.22 | -5.22 | 22.43 | -- | -- | -- | -- | 1,132,000.00 | -- | -17.65 | -- | -19.79 | 89.87 | -- | -23.28 | -97.72 | -- | -- | -- | -- | 198.56 | 117.25 | 58.42 | -- | 122.32 | -- |
Lonza Group AG | 51.57bn | 5.02bn | 278.49bn | 18.00k | 56.64 | 3.83 | 29.51 | 5.40 | 8.87 | 8.87 | 91.16 | 131.07 | 0.3928 | 2.80 | 5.84 | 373,166.70 | 3.83 | 5.07 | 4.64 | 6.21 | 29.00 | 39.15 | 9.75 | 14.52 | 1.20 | 11.86 | 0.2275 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
Holder | Shares | % Held |
---|---|---|
Polar Capital LLPas of 19 Oct 2023 | 5.65m | 9.02% |
J.O. Hambro Capital Management Ltd.as of 11 Jan 2024 | 3.13m | 4.99% |
The Vanguard Group, Inc.as of 06 Jun 2024 | 2.17m | 3.46% |
Fidelity Management & Research Co. LLCas of 30 Apr 2024 | 2.07m | 3.31% |
Norges Bank Investment Managementas of 31 Dec 2023 | 1.52m | 2.42% |
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 1.48m | 2.37% |
Schroder Investment Management Ltd.as of 29 Feb 2024 | 1.30m | 2.07% |
Handelsbanken Fonder ABas of 31 May 2024 | 1.09m | 1.74% |
TIAA-CREF Investment Management LLCas of 30 Apr 2024 | 882.28k | 1.41% |
Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 743.20k | 1.19% |